Saroglitazar magnesium is an experimental drug. It is dual peroxisome proliferator-activated receptor (PPAR)agonist. This means that the study drug is designed to provide anti-inflammatory effect, moderate blood sugar levels, and also help control lipids and lipoprotein metabolism (fat and how your body breakdown these fats).
The sponsor of this study, Zydus Discovery DMCC, wants to evaluate the safety and efficacy of Saroglitazar magnesium 2 mg and 4mg versus placebo in the treatment of Primary Biliary Cholangitis. This is a randomized, double-blinded clinical research study. Sometimes we do not know which treatment or which doses are best for treating a condition. To find out, we need to compare different treatments. People are put into groups and each group is assigned a different treatment. Then we check to see which treatment appears to work better. To try to make sure the groups are the same, each participant is put into a group by chance, like the flip of a coin (random). You will have a 2 in 3 chance of receiving the active study drug.
The research study being blinded means that neither you nor your study doctor will know which treatment you are receiving. However, in certain circumstances your study doctor can find out which treatment you are receiving by asking the sponsor.
If you qualify, you will randomly (like the flip of a coin) receive Saroglitazar magnesium 2 mg, Saroglitazar magnesium 4 mg, or placebo, by mouth once daily in the morning before breakfast without food for 16 weeks. A total of approximately 36 subjects will be randomized. You must be willing to attend all the visits to the doctor. Different procedures will be performed at each visit.
The research study consists of a Screening Phase (Visits 1 and 2) that lasts up to 42 days, a Treatment Phase (Visits 3 through 7) that will last 112 days, and a safety follow-up 4 weeks later. The research study lasts about 26 weeks.
How understandable was the trial content above?
Hard to understand
Easy to understand
